Venture Capital firm Asabys Partners closed its second fund, Sabadell Asabys Health Innovation Investments II, with total commitments of €180 million ($200 million). The funds will go towards 12 to 15 ...

The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...

In one of the largest private rounds raised by an Italian biotech, Genespire Srl has closed a €46.6 million (US$51.88 million) series B, enabling it to lay the ground for a phase I/II clinical trial ...

Insilico Medicine Inc. has synthesized cyclin-dependent kinase 8/19 (CDK8/19) dual inhibitors reported to be useful for the treatment of autoimmune disease and cancer.

Spanish VC firm Asabys Partners has closed its second fund at €180 million (US$201.3 million), to be invested in seed to ...

China’s National Medical Products Administration (NMPA) has accepted NDAs for Innovent Biologics Inc.’s IL-23p19 antibody ...

Endometrial cancer (EC) accounts for 20% to 30% of most malignant tumors of the female reproductive system, making it one of ...

A new series of proteolytic targeting chimeras (PROTACs) was designed by Zhejiang University of Technology scientists based ...

In some ways, remote patient monitoring (RPM) came of age during the COVID-19 pandemic, but payers still worry about the ...

Linda Marbán, Capricor’s CEO, is the guest on the newest BioWorld Insider podcast and she talks about deramiocel (CAP-1002), the company’s allogeneic cardiac-derived cell therapy, for treating the ...

In August 2024, BioWorld tracked 92 clinical trial updates, a decrease from the 121 reported in July. The month included nine successful phase III trials, three with mixed outcomes and three failures.

Evaxion Biotech A/S has entered into an option and license agreement with MSD (Merck & Co. Inc.) for two preclinical vaccine candidates.